1. Home
  2. CADL vs JGH Comparison

CADL vs JGH Comparison

Compare CADL & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$4.79

Market Cap

357.4M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Global High Income Fund of Beneficial Interest

JGH

Nuveen Global High Income Fund of Beneficial Interest

HOLD

Current Price

$11.91

Market Cap

285.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CADL
JGH
Founded
1999
2014
Country
United States
United States
Employees
55
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
357.4M
285.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CADL
JGH
Price
$4.79
$11.91
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$19.71
N/A
AVG Volume (30 Days)
1.2M
89.0K
Earning Date
03-12-2026
01-01-0001
Dividend Yield
N/A
9.85%
EPS Growth
58.62
N/A
EPS
N/A
N/A
Revenue
$125,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.25
$10.51
52 Week High
$7.24
$13.70

Technical Indicators

Market Signals
Indicator
CADL
JGH
Relative Strength Index (RSI) 42.63 25.35
Support Level $4.58 N/A
Resistance Level $5.42 $12.92
Average True Range (ATR) 0.24 0.16
MACD 0.01 -0.04
Stochastic Oscillator 28.15 5.26

Price Performance

Historical Comparison
CADL
JGH

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About JGH Nuveen Global High Income Fund of Beneficial Interest

Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.

Share on Social Networks: